Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 15

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 15
---
 | Developing therapeutic and diagnostic innovations across a wide range of disease/therapeutic areas; |

| ● | Selectively expanding our portfolio with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical needs; |

| ● | Collaborating with leading academic institutions and CROs; |

| ● | Expanding our in-house pharmaceutical development center; |

| ● | Leveraging our management’s expertise, experience and commercial networks; |

| ● | Obtaining and leveraging government grants to fund project development. |

Aptorum’s Lead Projects are ALS-4 and SACT-1. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body’s systems. These products of bacterial genes are referred to as “virulence expression.” Targeting bacterial virulence is an alternative approach to antimicrobial therapy that offers promising opportunities to overcome the emergence and increasing prevalence of antibiotic-resistant bacteria. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT ®drug discovery platform. SCAT-1 is one of the Company’s proprietary technologies. Our first targeted indication is neuroblastoma. Neuroblastoma is a rare form of cancer, and classified as an orphan disease, that forms in certain types of nerve tissue and most frequently in the adrenal glands as well as spine, chest, abdomen or neck, predominantly in children, especially for those aged 5 years and below.

<div align='center'>1</div>

In March 2023, Aptorum
announced that it completed the Pre-IND discussions with the US FDA on ALS-4. With the positive feedback on the overall development strategy
from the US FDA, it is proceeding towards the IND submission of ALS-4. In March 2023, Aptorum also announced the completion of the
End of Phase 1 (EOP1) meeting of SACT-1 with the US FDA. The FDA generally agreed with the chemistry-manufacturing-control (CMC)
strategy and Aptorum’s proposed clinical development plan for SACT-1 Phase 1/2 trials. The timing and scope of advancing both
ALS-4 Phase 2 clinical trials and SACT-1 Phase 1/2 trials will be contingent upon securing appropriate collaborative partnerships
and adequate funding resources. The Company is actively seeking strategic collaborators who can provide both financial support and clinical
expertise to advance these therapeutic programs